Effectively inhibiting the level of sEH or co-inhibition of sEH with other inhibitors can have a good protective effect on renal-associated diseases, such as AKI, CKD and DN, which has been effectively verified in several researches. This evidence concerns the gene EPHX2 and liver dysplastic nodule.